If your commercial team is still segmenting physicians the way you did in 2018 — decile tiering, specialty cuts, three loyalty buckets — there’s a good chance your rep coverage looks busy and your prescriptions look flat. The disconnect isn’t about effort. It’s about a framework that has aged faster than the market it was built for.
Consider what’s happening at the top of the house. According to Deloitte’s 2026 Life Sciences Outlook, only 22% of life sciences leaders said they have successfully scaled AI in their business, and just 9% reported significant returns on those investments. The pipes are being built; the value is leaking somewhere between strategy and the field.
Read More: How Can AI for support teams Simplify Their Tasks
Polestar Analytics helps pharma organizations bridge this gap by connecting data, analytics, and commercial decision-making.
This is where HCP segmentation for pharma earns its keep. Done well, it tells you which physician deserves which conversation, on which channel, at which moment. Done poorly, it tells you who to ignore — and that’s where commercial value quietly dies.
What is HCP Segmentation in Pharma?
In the pharma industry, HCP segmentation refers to the way that pharma companies organize individual HCPs (primary care physicians, specialists, nurse practitioners, thought leaders, etc.) into groups (segments) based on the fact that they collectively have certain commercial characteristics (i.e., prescribing patterns, patient populations, preferred channels, level of scientific interest, level of access to payers, willingness to utilise a new therapy).
Why is this central to HCP in pharma industry today? Because the average specialist now interacts with a small handful of pharma companies and politely ignores the rest. The structural pressures don’t help either. BCG’s Biopharma Trends 2026 report notes that average total shareholder return across the sector flatlined at 0% from 2021 to 2025, compared with 16% for the S&P 500. There is no slack left in the commercial model for spray-and-pray targeting. This is where Polestar Analytics brings data-driven HCP segmentation into the commercial strategy.
Why the traditional Decile Model Is Outdated
Decile-based targeting was never wrong — it was incomplete. It sorts physicians by historical Rx volume. It does not tell you why Dr. X writes what she writes, whether her patient panel has changed, or whether her hospital quietly moved to a new formulary last quarter. It is a rear-view mirror dressed up as a strategy.
What commercial teams are struggling with now is multidimensional. A high-decile cardiologist may be locked out by a payer block. A low-decile pulmonologist may be sitting on a panel of newly diagnosed patients ready for a switch. A digital-savvy endocrinologist may never open an email but will sit through an on-demand webinar twice. Treat them all the same and your investment thins to a film.
HCP Segmentation Frameworks That Actually Work
There is no universal framework, but the strong ones share a structure. Most mature commercial organisations now run HCP segmentation in pharmaceutical industry contexts on three overlapping lenses.
Behavioural segmentation comes from the hard numbers — prescribing patterns, switch behaviour, patient acquisition velocity, treatment persistence. This gives the model its quantitative spine.
Attitudinal segmentation draws on primary research and field intelligence — risk appetite for new therapies, scientific orientation, peer influence, attitude toward the brand. It’s the layer reps know in their gut, but most models quietly miss.
Channel and engagement segmentation lives in the digital trail — email opens, portal usage, conference attendance, content downloads. Behaviour and attitude tell you who to engage and why. This one tells you how to reach them.
Polestar Analytics applies these multidimensional signals to help pharma teams build more actionable HCP segments.
Layer these and you stop selling to averages. You start engaging a defined HCP archetype — say, a “scientifically restless early-adopter with strong payer access and a preference for asynchronous content” — and your messaging architecture begins to write itself.
HCP Segmentation Challenges in Pharmaceutical Industry
Let’s not pretend any of this is easy. Most teams hit the same walls.
Data is the first one. Rx claims live with one vendor, CRM activity with another, medical engagements somewhere else, and patient-level real-world evidence in a third silo. Stitching these into a single physician view is not a weekend project. The FDA’s growing reliance on real-world evidence has actually raised the stakes — your segmentation now has to hold up under both commercial and regulatory scrutiny.
The second wall is identity. A single HCP may have three NPI numbers, two affiliations, and a relocating address. Without a clean master data layer, your “segments” are a polite fiction.
The third is shelf-life. A segmentation built in January is stale by July. Physician behaviour shifts with formulary updates, label changes, competitive launches, and patient mix. Dynamic refresh is not a luxury; it is the model.
The fourth, and the most underrated, is field adoption. Segmentation that lives inside a deck nobody reads is worse than no segmentation at all. Reps need it inside the CRM, in plain language, with a clear “why this HCP, why now, why this message.”
AI-Powered HCP Targeting Platforms: What Has Actually Changed
AI-powered HCP targeting platforms have quietly moved from prediction-only tools to orchestration engines. They unify Rx, claims, CRM, payer, and engagement signals, score each HCP across multiple intents, and surface the next-best action at the point of need — a rep visit, an email sequence, a webinar invite, or, occasionally, a deliberate no-contact window.
Read More: Threat Actor Profiling Data: Understanding Who Is Coming for You
The good ones share three traits. They are explainable — a rep can see why an HCP scored where she did. They are continuously refreshed, not quarterly. And they sit inside the workflow, not next to it.
A note of caution. AI does not absolve you of governance. FDA’s Office of Prescription Drug Promotion still bind every targeting decision. Compliance, content approval, and consent management need to be engineered into the platform from day one, not bolted on later.
Polestar Analytics supports this shift toward AI-powered, data-driven commercial decision-making for pharma organizations.
FAQs
Is the decile model still relevant for HCP segmentation in pharma?
Yes, but only as one input among several. Deciles still capture historical Rx volume accurately — modern HCP segmentation layers behavioural, attitudinal, and channel data on top to drive sharper targeting decisions.
Which HCP segmentation framework should pharma companies build first? Behavioural segmentation, in most cases. Rx, claims, and switch data are usually already accessible in-house, providing a quantitative foundation that attitudinal and channel-based segmentation layers can refine later.
How often should the segmentation of HCPs be updated?
Generally, established brands require quarterly updates, whereas new product launches are much more likely to have monthly updates or more frequent updates depending on payer concerns and evolving therapy options.
What should an HCP segmentation surface inside the CRM for field reps?
Three elements — the segment the HCP belongs to, the reason they are a priority right now, and the recommended next-best message or channel. Anything beyond this reduces field adoption.
The Bottom Line
HCP segmentation for pharma is no longer a research deliverable. Brands with successful marketing operations are known to operate at a higher level than their competition simply because they are taking advantage of fewer but more targeted and relevant marketing campaigns that are based on a data-driven segmentation method of learning.
The deciles remain a metric for all brands; however, they have become only one piece of a much larger array of key operational metrics that will help marketers understand how to allocate resources more effectively.
The new model rewards the teams that can connect data they already own, refresh their view of the physician faster than the market changes, and let the field execute against a story that holds together. Everything else is volume — and volume, as every commercial leader has learned the hard way, is not strategy. Polestar Analytics helps life sciences organizations turn this data-driven approach into actionable commercial intelligence.
